~~<i id='4D6C252277'><strike id='4D6C252277'><tt id='4D6C252277'><pre id='4D6C252277'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：Wikipedia 2025-09-04 05:36:38 - browse：869

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Yancopoulos of Regeneron works to expand Dupixent success

leisure time

explore

knowledge

hotspot

explore

hotspot

GeoffMartha,CEOofMedtronicCourtesyMedtronicAsoneofthelargestandoldestmedicaldevicecompaniesintheworl

WSS

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

6 surprising facts about sugar

Erich Jarvis studies song birds to learn about human stuttering

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Paying for Covid pills will soon shift to insurers

Why Sanofi got shellacked over its spinoff

focus

focus

leisure time

The high cost of giving birth even with insurance

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Tori Bowie and the unacceptable rates of Black maternal death

Diabetes management: Digital health tools fall short, study says

Virginia high school admissions case could be legal follow

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pfizer, Moderna say biotech, pharma drug development is a sprint

Continuity nursing helped my family in our darkest PICU moments

Surgeons perform first xenotransplant using CRISPR'd pig kidney

explore

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Why Sanofi got shellacked over its spinoff

WHO may add ‘noma' to its list of neglected tropical diseases

Medtronic CEO on promising devices for diabetes, hypertension

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Cancer, immunology, HIV research ensnared in fetal tissue politics

knowledge

hotspot

explore

hotspot